๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

26 recruiting trials

for PIK3CA Mutation

A Phase 2 Study of Mutant-selective PI3Kฮฑ Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) NCT06789913Phase 240 sites๐Ÿ“ Phoenix๐Ÿ“ Little Rock๐Ÿ“ Los Angeles Relay Therapeutics, Inc. ยท Tests: RLY-2608, Placebo A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600n/a32 sites๐Ÿ“ Xiamen๐Ÿ“ Lanzhou๐Ÿ“ Shijiazhuang Hoffmann-La Roche ยท Tests: Inavolisib, Palbociclib, Fulvestrant Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites๐Ÿ“ Aviano๐Ÿ“ Brescia๐Ÿ“ Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ยท Tests: Palbociclib, Ribociclib, Abemaciclib A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites๐Ÿ“ Scottsdale๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto Cogent Biosciences, Inc. ยท Tests: CGT6297 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites๐Ÿ“ Gilbert๐Ÿ“ Beverly Hills๐Ÿ“ Duarte Relay Therapeutics, Inc. ยท Tests: Zovegalisib, Capivasertib, Fulvestrant A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer NCT07405801Phase 258 sites๐Ÿ“ Anaheim๐Ÿ“ Palo Alto๐Ÿ“ Jacksonville Hoffmann-La Roche ยท Tests: Inavolisib, Ribociclib, Fulvestrant, Placebo Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma NCT07795528n/a1 site๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer NCT07054190Phase 237 sites๐Ÿ“ Los Angeles๐Ÿ“ Orange๐Ÿ“ Germantown Hoffmann-La Roche ยท Tests: Inavolisib, Ribociclib, Letrozole, Giredestrant First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139Phase 1, Phase 265 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Aurora Eli Lilly and Company ยท Tests: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy NCT05646862Phase 3210 sites๐Ÿ“ Greenbrae๐Ÿ“ Los Alamitos๐Ÿ“ Los Angeles Hoffmann-La Roche ยท Tests: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer NCT07368998Phase 234 sites๐Ÿ“ Los Angeles๐Ÿ“ Jacksonville๐Ÿ“ Kansas City Hoffmann-La Roche ยท Tests: Inavolisib, Fulvestrant Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. NCT05948943Phase 2, Phase 361 sites๐Ÿ“ Oakland๐Ÿ“ Orange๐Ÿ“ Palo Alto Novartis Pharmaceuticals ยท Tests: Alpelisib, Placebo A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) NCT07174336Phase 3363 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Phoenix Eli Lilly and Company ยท Tests: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib REC-7735 in Participants With Solid Tumors NCT07819136Phase 1, Phase 23 sites๐Ÿ“ Grand Rapids๐Ÿ“ Irving๐Ÿ“ Fairfax Recursion Pharmaceuticals Inc. ยท Tests: REC-7735 Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer NCT05455619Phase 1, Phase 210 sites๐Ÿ“ Loma Linda๐Ÿ“ Newport๐Ÿ“ San Diego SynDevRx, Inc. ยท Tests: Evexomostat Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites๐Ÿ“ Los Angeles๐Ÿ“ Lone Tree๐Ÿ“ Springfield Faeth Therapeutics ยท Tests: Serabelisib, Sapanisertib, Fulvestrant Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors NCT06993844Phase 1, Phase 215 sites๐Ÿ“ Newport Beach๐Ÿ“ San Francisco๐Ÿ“ New Haven Ensem Therapeutics ยท Tests: ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combinationโ€ฆ A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer NCT05894239Phase 3192 sites๐Ÿ“ Gilbert๐Ÿ“ Burbank๐Ÿ“ Corona Hoffmann-La Roche ยท Tests: Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. NCT07207070Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Zhengzhou Risen (Suzhou) Pharma Tech Co., Ltd. ยท Tests: JS105, Dalpiciclib, Fulvestrant 50 Mg/mL Intramuscular Solution Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer NCT06463028Phase 218 sites๐Ÿ“ La Jolla๐Ÿ“ San Francisco๐Ÿ“ Miami Beach Faeth Therapeutics ยท Tests: Sapanisertib, Serabelisib, Paclitaxel GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors. NCT07407504Phase 11 site๐Ÿ“ Beijing Changchun GeneScience Pharmaceutical Co., Ltd. ยท Tests: GenSci145 tablets A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes NCT07748208Phase 210 sites๐Ÿ“ Washington D.C.๐Ÿ“ Atlanta๐Ÿ“ Atlanta Hoffmann-La Roche ยท Tests: Inavolisib, Fulvestrant, Palbociclib Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors NCT07524322Phase 15 sites๐Ÿ“ Los Angeles๐Ÿ“ Houston๐Ÿ“ Houston Regor Pharmaceuticals Inc. ยท Tests: RGT-490 A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer NCT06790693Phase 3242 sites๐Ÿ“ Goodyear๐Ÿ“ Phoenix๐Ÿ“ Burbank Hoffmann-La Roche ยท Tests: Inavolisib, Placebo, CDK4/6i, Letrozole A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations NCT05983159Phase 22 sites๐Ÿ“ Parkville๐Ÿ“ Parkville Murdoch Childrens Research Institute ยท Tests: Alpelisib, Mirdametinib First-in-Human Study of Mutant-selective PI3Kฮฑ Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer NCT05216432Phase 137 sites๐Ÿ“ Tucson๐Ÿ“ San Diego๐Ÿ“ Denver Relay Therapeutics, Inc. ยท Tests: RLY-2608, Fulvestrant, Palbociclib 125mg, Ribociclib 400mg, Ribociclib 600mg
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy